Search our database of publications on vaccines for COVID-19. These include published scientific papers, preprints and policy reports, and all are from teams based in the UK.
Encouraging results have been observed from initial studies evaluating vaccines targeting the novel beta coronavirus which causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). BNT162b2 (Pfizer- BioNTech) is a nucleoside-modified mRNA that encodes a full-length SARS-CoV-2 Spike (S) protein, a key target of neutralising antibodies, and has demonstrated a 95% reduction of cases in the general population. However, concerns have been raised around the efficacy of these vaccines in immunosuppressed populations, including patients with haematological malignancy.